This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nathan Sadeghi-Nejad


Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza┬┐s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Nathan Sadeghi-Nejad
By This Author:
Page 2 of 5

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

By Nathan Sadeghi-Nejad

A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.

06:00AM 10/15/12

Sarepta Shares Still Have Upside

By Nathan Sadeghi-Nejad

Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.

10:43AM 10/03/12

Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

By Nathan Sadeghi-Nejad

Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302

07:30AM 10/01/12

A New Reason to be Bullish About Sarepta Therapeutics

By Nathan Sadeghi-Nejad

A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.

07:00AM 09/24/12

Idenix Pharma: Guilty By Association

By Nathan Sadeghi-Nejad

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

07:48AM 09/21/12

Bull Case on Peregrine Pharma Shouldn't Be Dismissed

By Nathan Sadeghi-Nejad

Believers in Peregrine's lung cancer drug bavituximab state their case.

09:33AM 09/17/12

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

By Nathan Sadeghi-Nejad

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

11:53AM 09/10/12

More Reasons to Invest in Sarepta With Caution

By Nathan Sadeghi-Nejad

Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.

10:35AM 08/27/12

Sarepta's Risks Shouldn't Be Ignored

By Nathan Sadeghi-Nejad

There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.

07:00AM 08/21/12

In These Turbulent Times, Reach for Merck

By Nathan Sadeghi-Nejad

The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.

09:03AM 08/13/12

Page 2 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs